Evidence map›Paper›PMID 28063866›Full record

ArticleJournal of pain and symptom management2017

Chemotherapy-Induced Neuropathy in Cancer Survivors.

Christine Miaskowski, Judy Mastick, Steven M Paul, Kimberly Topp, Betty Smoot, Gary Abrams, Lee-May Chen, Kord M Kober, Yvette P Conley, Margaret Chesney and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pain and symptom management, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 3 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 121 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Changes in opioid prescribing and high-risk co-prescribing after implementation of the 2016 CDC opioid guideline among older adults with and without cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  9. Article
  10. Article
  11. Large fiber contribution to symptoms in chemotherapy-induced peripheral neuropathy in cancer survivors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  12. Frailty and neuropathy in chemotherapy patients: moderated mediation roles of fatigue and mindfulness on CIPN, anxiety, and depression.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Christine MiaskowskiSchool of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
Judy MastickSchool of Nursing, University of California, San Francisco, California, USA.
Steven M PaulSchool of Nursing, University of California, San Francisco, California, USA.
Kimberly ToppSchool of Medicine, University of California, San Francisco, California, USA.
Betty SmootSchool of Medicine, University of California, San Francisco, California, USA.
Gary AbramsSchool of Medicine, University of California, San Francisco, California, USA.
Lee-May ChenSchool of Medicine, University of California, San Francisco, California, USA.
Kord M KoberSchool of Nursing, University of California, San Francisco, California, USA.
Yvette P ConleySchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Margaret ChesneySchool of Medicine, University of California, San Francisco, California, USA.
Kay BollaSchool of Nursing, University of California, San Francisco, California, USA.
Grace MausisaSchool of Nursing, University of California, San Francisco, California, USA.
Melissa MazorSchool of Nursing, University of California, San Francisco, California, USA.
Melisa WongSchool of Medicine, University of California, San Francisco, California, USA.
Mark SchumacherSchool of Medicine, University of California, San Francisco, California, USA.
Jon D LevineSchool of Medicine, University of California, San Francisco, California, USA.
University of California, San Francisco · USUniversity of Pittsburgh · US

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
VARC CoreP30AG044281 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Keliimoeanu Smith · 2013 to 2026
$19.9M
RESEARCH TRAINING IN GERIATRIC MEDICINET32AG000212 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Alexander Keliimoeanu Smith · 1991 to 2026
$7.7M
Characterization of and Treatment for Chemotherapy NeuropathyR01CA151692 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2011 to 2015
$6.4M
Advancing the Science of Symptom Management in Oncology PatientsK05CA168960 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MIASKOWSKI, CHRISTINE A. · 2013 to 2017
$453k
NCATS NIH HHS UL1 TR000004NCI NIH HHS K05 CA168960NCI NIH HHS R01 CA151692NIA NIH HHS P30 AG044281NIA NIH HHS T32 AG000212
6 · The paper itself

Abstract

contextEvidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available.

objectivesTo evaluate between-group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n = 426) and did not (n = 197) develop CIN.

methodsSurvivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go test, Fullerton Advanced Balance test). Parametric and nonparametric statistics were used to compare between-group differences in study outcomes.

resultsOf the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included the following: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function, and balance.

conclusionsThis study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.

Indexed as

Cancer SurvivorsAntineoplastic AgentsFemaleHumansMaleMiddle AgedPeripheral Nervous System DiseasesPhysical ExaminationPlatinum CompoundsSelf ReportTaxoidsAntineoplastic AgentsPlatinum CompoundsTaxoidsbalancecancerchemotherapyChemotherapy-induced neuropathygaitpainpain qualitiessensationsvibration

Identifiers

PMID28063866
PMCPMC5496793
OpenAlexW2571321248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.